Innovent Biologics, Inc. is a world-class biopharmaceutical company founded in 2011 that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases. The company has built a robust pipeline of 36 valuable assets, including 22 in oncology. As of 2024, Innovent has launched 10 products in the market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab biosimilar injection), SULINNO (adalimumab biosimilar injection), HALPRYZA (rituximab biosimilar injection), PEMAZYRE (pemigatinib oral inhibitor), olverembatinib, CYRAMZA (ramucirumab injection), Retsevmo (selpercatinib capsules), FUCASO (equecabtagene autoleucel injection) and SINTBILO (tafolecimab injection). The company has four new drug applications under regulatory review, five assets in Phase III or pivotal clinical trials, and 18 more molecules in early clinical stage. Innovent's research and development strategy is centered on global innovation, with a focus on the "IO + ADC" approach in oncology. The company has established manufacturing facilities in Suzhou and Hangzhou, with a total antibody production capacity of 230,000L. In 2023, Innovent reported total revenue of RMB6,206.1 million, an increase of 36.2% compared to 2022.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.